Navigation Links
NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
Date:10/29/2009

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Chief Financial Officer and Executive Vice President, will present at the Oppenheimer 20th Annual Healthcare Conference at The Waldorf Astoria Hotel in New York, New York, on Tuesday, November 3, 2009.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's later
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
2. NuVasive to Present at the JMP Securities Healthcare Focus Conference
3. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
4. BioCryst to Present at Oppenheimer Healthcare Conference
5. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
8. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
11. Rigel Announces Presentations at Two Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced the ... - November 19-20, 2015)" conference to their offering. ... industry case studies, regulatory updates, latest therapies and technology ... Steven Nichols , OINP Specialist Consultant and Mike ... participating include: - Aptar Pharma ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the ... - November 16-18, 2015)" conference to their offering. Regulatory ... including Columbia, Peru , Brazil , ... Uruguay , Paraguay , Venezuela ... Chile This seminar can be viewed ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each ... among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and ... year, that process led the magazine to tap the National League for Nursing’s ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Symposium (WFS), cosponsored by the Military Officers Association of America (MOAA) and ... "Our Nation's Military: Caring For Our Own,” expert panelists will lead interactive ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... (blinatumomab) – in the news recently following a decision by the Centers for ... – is likely to average approximately $71,000 or roughly 40% of its headline-grabbing ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... pregnant, but visiting a behavioural therapist for a few ... ,Emory University gynaecologist Sarah Berga examined the value ... had stopped ovulating. ,When presenting her findings ... study of 16 women was small and that a ...
... this year in Assam, state Health Minister Himanta Biswa Sarma ... cut motions in the state assembly, Sarma said the exact ... not reached the state capital., ,Admitting that last year ... per cent of the affected area has been covered., ...
... affairs, China today nominated Hong Kong's Margaret Chan to ... Organisation (WHO).// ,Chan currently serves as WHO ... Director- General will be in November this year., ... Jong-wook from South Korea in May this year., ...
... to be infected with a strain of bird flu that may ... Ministry official// Yukol Limlaemthong on Monday. ,Yukol said, "There ... the area has had outbreaks before." ,Officials have ... was in the northern province of Pichit. This was one of ...
... on the heels of banning illegal organ transplants, China ... panacea for a range of blood disorders. ... Ministry of Health said that the sources of peripheral ... registered sources that can be traced., ,The regulations ...
... China's health insurance companies will offer a special policy for ... policy will be available from August 8 after the insurance ... ,It will be valid for 30 days and ... cost 88 yuan ($11) and compensation will include 10,000 yuan ...
Cached Medicine News:Health News:Stress Therapy can Restore Fertility: Study 2
Store microscope slides with ease, speed, efficiency....
... drawers for just about everything imaginable that might ... Each box is designed for long term storage ... of wood over metal systems is overlooked, while ... subtle kind of desiccator and insulator, providing an ...
A prepared Microscope Slide Cataloging and Storage System....
... resistant, plastic covered corrugated boxes interlock ... up to 500 lbs of overhead ... accommodates 2000 slides or 500 tissue ... requirements. Come unassembled boxes require minimal ...
Medicine Products: